stockrowElutia Inc.
ELUT Healthcare Medical Devices
Elutia Inc.’s revenue for fiscal 2025 (year ended December 2025) was $12.3 million, down 15.0% from fiscal 2024.
- Revenue
- −11.7%
- EPS
- +26.1%
- Free cash flow
- −2.52%
Quarter to June 2026, against a year earlier
Follow ELUT
Alert me
Elutia Inc. (ELUT) EV/Sales
As of 5 November 2026, Elutia Inc. (ELUT) trades at a EV/Sales of 3.4×. Over the past ten years it has ranged from 0.0× (December 2020) to 8.1× (July 2025); the current reading is higher than 56% of that period. That is above the Medical Devices industry median of 2.7× and in line with the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.5× | (72.37%) |
| FY2024 | 5.4× | 168.13% |
| FY2023 | 2.0× | (36.71%) |
| FY2022 | 3.2× | 179.89% |
| FY2021 | 1.1× | (56.94%) |
| FY2020 | 2.6× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.1× | 18.92% |
| Mar 2026 | 3.4× | 130.23% |
| Dec 2025 | 1.5× | (63.47%) |
| Sep 2025 | 4.1× | (39.07%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NNOX Nano-X Imaging Ltd. compare | −0.5× |
| NSYS Nortech Systems Incorporated compare | 0.2× |
| XTNT Xtant Medical Holdings, Inc. compare | 0.5× |
| CVRX CVRx, Inc. compare | 0.7× |
| RPID Rapid Micro Biosystems, Inc. compare | 0.8× |
| TELA TELA Bio, Inc. compare | 1.0× |
| QTI QT Imaging Holdings, Inc. compare | 1.3× |
| NSPR InspireMD, Inc. compare | 2.5× |
| ELUT Elutia Inc. | 3.4× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)